Sigrid Sanchez, M.D.; Decision and Order, 39331-39336 [2013-15706]
Download as PDF
mstockstill on DSK4VPTVN1PROD with NOTICES
Federal Register / Vol. 78, No. 126 / Monday, July 1, 2013 / Notices
because the applicant/registrant may
have a valid explanation for why it is
not currently licensed by the state,
which would not necessarily support
either revocation of an existing
registration or the denial of an
application. For example, the state
licensing authority may have a large
backlog in issuing its licenses, the
applicant/registrant’s application may
have been lost or misplaced, there may
be minor compliance issues which the
applicant/registrant is in the process of
correcting and which have delayed the
issuance of the license but which would
not necessarily warrant a denial or
revocation (as the case may be) by DEA,
or the applicant/registrant may have
simply forgotten to renew its license on
time. However, because other than in
the case of practitioners, the possession
of state authority is not an independent
requirement for registration, what is
clear is that an applicant/registrant is
entitled to rebut the Government’s
prima facie case by showing that its
conduct is not sufficiently egregious to
warrant denial or revocation and what
remedial measures it has undertaken to
correct the problem. Thus, upon a
proper showing by a respondent,
summary disposition would be
unwarranted and the respondent would
be entitled to put on evidence.
In this matter, it is noted that in his
July 14, 2011 filing, Respondent’s owner
claimed that it had filed for a renewal
of its state license. However, since then,
Respondent has produced no evidence
that it has obtained a new state license.
In addition, Respondent failed to
comply with the ALJ’s order for
prehearing conference and failed to
respond to the Government’s renewed
motion for summary disposition. As the
First Circuit has noted in language that
applies with equal force to
administrative proceedings, ‘‘‘[l]itigants
must act punctually and not casually or
indifferently if a judicial system is to
function effectively.’’’ McKinnon v.
Kwong Wah Restaurant, 83 F.3d 498,
504 (1st Cir. 1996) (quoted in Kamir
Garces-Mejias, 72 FR 54931, 54933
(2007) (holding that registrant’s failure
to respond to ALJ’s orders constituted
waiver of her right to a hearing)). I
therefore conclude that Respondent has
waived its right to present evidence
regarding its compliance with
applicable laws. See Garces-Mejias, 72
FR at 54932–33; see also Pamela
Monterosso, 73 FR 11146, 11147 (2008).
In addition, as I noted in the remand
order, Respondent applied for a
distributor’s registration, and paid the
fee for this category of registration (and
not the fee for a manufacturer’s
VerDate Mar<15>2010
21:38 Jun 28, 2013
Jkt 229001
registration).7 However, it is clear from
Respondent’s application that it sought
to engage in the ‘‘Preparation 5%
Solution (Lugol’s Solution)’’ and then
noted that it intended to manufacture
iodine in the dosage formulation of ‘‘8
ml each.’’ This constitutes
manufacturing activity under the CSA.
See 21 U.S.C. 802(15) (defining
manufacturing to include ‘‘the
production, preparation . . . or
processing of a drug or other substance,
either directly or indirectly . . . and
includes any packaging or repackaging
of such substances or labeling or
relabeling of its container’’).
Under the CSA, ‘‘[p]ersons registered
. . . to manufacture, distribute, or
dispense controlled substances or list I
chemicals are authorized to possess,
manufacture, distribute, or dispense
such substances or chemicals . . . to the
extent authorized by their registration.’’
Id. § 822(b). Under DEA regulations, the
manufacturing and distribution of list I
chemicals are activities which ‘‘are
deemed to be independent of each
other’’ and while the holder of a
manufacturer’s registration can engage
in the distribution of a list I chemical,
the holder of a distributor’s registration
cannot engage in manufacturing. 21 CFR
1309.21(c); id. 1309.22(b) & (d).
Accordingly, Respondent’s proposed
activity would not be lawful under the
registration it seeks.
Based on Respondent’s failure to
obtain the required state permit or
license, as well as that its proposed
activity would not be lawful under the
registration for which it applied, I find
that the record supports a finding under
factor two that granting Respondent’s
application would be ‘‘inconsistent with
the public interest.’’ 21 U.S.C. 823(h).
Accordingly, Respondent’s application
will be denied.8
7 In his letter requesting a hearing, Respondent’s
owner stated that it required a DEA registration ‘‘to
manufacture iodine 5% solution, called Lugol
Solution.’’ Letter of Paul Anand, Ph.D., to
Administrator (June 23, 2011). However, according
to Respondent’s application, it sought registration
as a Chemical Distributor and not as a Chemical
Manufacturer; consistent with this, it paid the fee
for the former and not the latter. Respondent’s
Application, at 1, 3. Moreover, in Section 3B of the
application, which applies to ‘‘Manufacturers
Only,’’ Dr. Anand wrote: ‘‘Preparation 5% Solution
(Lugol’s Solution),’’ and in Section 3C, he checked
the box for bulk iodine. Id. at 1–2.
Under DEA’s regulation, the manufacturing of list
I chemicals is deemed to be an activity which is
independent of distribution (although a registered
manufacturer can lawfully engage in distribution),
and thus requires a manufacturer’s registration. See
21 CFR 1309.22. Because Respondent did not apply
for the required registration, its application should
have been rejected as defective. See id. § 1309.34(a).
8 As found above, on November 2, the
Government filed its second motion for summary
disposition by mailing it to Respondent’s owner, at
PO 00000
Frm 00081
Fmt 4703
Sfmt 4703
39331
Order
Pursuant to the authority vested in me
by 21 U.S.C. 823(h) and 28 CFR
0.100(b), I order that the application of
Bio Diagnostic International, Inc., for a
DEA Certificate of Registration as a
distributor of list I chemicals, be, and it
hereby is, denied. This Order is effective
July 31, 2013.
Dated: June 21, 2013.
Michele M. Leonhart,
Administrator.
[FR Doc. 2013–15704 Filed 6–28–13; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Sigrid Sanchez, M.D.; Decision and
Order
On February 4, 2011, the Deputy
Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration, issued an Order to
Show Cause to Sigrid A. Sanchez, M.D.
(Respondent), of Sunrise, Florida. The
Show Cause Order proposed the denial
of Respondent’s pending application for
a DEA Certificate of Registration as a
practitioner, on the ground that her
‘‘registration would be inconsistent with
the public interest.’’ GX 7, at 1 (citing
21 U.S.C. 823(f)).
More specifically, the Show Cause
Order alleged that on May 19, 2010,
Respondent had surrendered her
previous DEA registration, and that on
July 29, 2010, she had applied for a new
registration. Id. The Show Cause Order
further alleged that on April 30, 2010,
the Florida Department of Health had
conducted ‘‘a dispensing practitioner’s
its address in Brea, California; on November 9, the
ALJ issued his recommended decision noting that
‘‘Respondent had ‘until 4:00 p.m. EDT three
business days after the date of service of any motion
to file a responsive pleading’ and that ‘[i]n the
absence of good cause, failure to file a written
response to the moving party’s motion after three
business days will be deemed a waiver of
objection.’’’ ALJ II, at 4. The ALJ apparently deemed
service to have been effectuated with mailing. See
id. (noting that ‘‘[a]s of November 9, 2011, five
business days after service of the Government’s
[motion], Respondent had not yet filed a
response’’). While courts frequently deem service of
a pleading to have occurred on mailing and not
upon receipt by the opposing party, see, e.g.,
F.R.C.P. r. 5(b)(2)(C), due regard must be given to
the respective locations of the parties and the
vagaries of the mail. While an ALJ is entitled to
substantial discretion in managing his/her docket,
the amount of time the ALJ allowed here for
Respondent to file its responsive pleading was
unduly limited and potentially a violation of Due
Process.
However, because following issuance of the
remand order, Respondent has not filed any
pleadings including exceptions, I deem any such
error harmless.
E:\FR\FM\01JYN1.SGM
01JYN1
mstockstill on DSK4VPTVN1PROD with NOTICES
39332
Federal Register / Vol. 78, No. 126 / Monday, July 1, 2013 / Notices
inspection’’ at Respondent’s former
registered location, the Mercy Wellness
and Recovery Center of Fort Lauderdale,
Florida, finding violations of both
federal and state law. Id.
The Order alleged that the federal
violations included, inter alia, failing to
provide adequate supervision over
employees who had access to
controlled-substance storage areas,
failing to store controlled substances in
a securely locked cabinet, taking
possession of controlled substances at
the clinic upon commencing her
employment while failing to conduct an
inventory of the controlled substances,
failing to supervise the dispensing of
controlled substances by clinic
employees, authorizing an employee to
order schedule II controlled substances
without executing a Power of Attorney,
and not having ‘‘an adequate system for
monitoring the receipt, distribution and
disposition of controlled substances.’’
Id. at 1–2 (citing 21 CFR 1301.71(a),
(b)(11), (b)(14); 1301.75(b); 1304.21(a);
1304.22).
With respect to the state violations,
the Show Cause Order alleged that ‘‘by
the transfer of controlled substances,’’
Respondent violated various provisions
of Floria law. Id. at 2 (citing Fla. Stat.
Ann. §§ 499.0051(1), 499.006(10), and
499.0121(6) (all 2010)). The Order also
alleged that Respondent’s ‘‘failure to
supervise and review the dispensing of
controlled substances’’ violated both
Florida statutes and regulations. Id.
(citing Fla. Stat. Ann. § 893.04(1)(b)
(2010); Fla. Admin. Code Ann. r.
64B16–27.1001(3) & (4) (2010); id. r.
64B16–28.140(3) (2010)). Finally, the
Show Cause Order alleged that
Respondent also violated state
controlled substance recordkeeping
requirements. Id. (citing Fla. Stat. Ann.
§§ 893.07(1)(a) & (b); 893.07(2)).1
In a letter dated February 16, 2011,
Respondent acknowledged service of
the Show Cause Order. In her letter,
Respondent further stated that she was
waiving her right to a hearing but
submitting a ‘‘written statement
regarding [her] position on the matters
of fact and law involved.’’ GX 6. See
also 21 CFR 1301.43(c). Respondent’s
statement was made a part of the record.
See GX 6. On September 20, 2011, the
record was forwarded to my Office for
Final Agency Action.
Having considered the entire record
(including Respondent’s statement), I
conclude that granting Respondent’s
application would be inconsistent with
1 The Show Cause Order also notified Respondent
of her right to request a hearing on the allegations
or to submit a written statement in lieu of a hearing,
the procedures for electing either option, and the
consequences for failing to do so. GX 7, at 3.
VerDate Mar<15>2010
21:38 Jun 28, 2013
Jkt 229001
the public interest. Accordingly,
Respondent’s application will be
denied. I make the following findings.
Findings
Respondent previously held a DEA
Certificate of Registration as a
practitioner in schedules II through V.
GX 1, at 1. On April 7, 2010,
Respondent changed her registered
address to 2001 N E 48th St., Fort
Lauderdale, Florida. Id. This address
was the location of the Mercy Wellness
and Recovery Center (hereinafter,
Mercy), a pain management clinic. GX
5, at 59. On or about April 13, 2010,
Respondent, who is board certified in
internal medicine, became the clinic’s
medical doctor. Id. at 1, 48, 60.
According to a sworn statement
Respondent gave to Investigators of the
Florida Department of Health (DOH), in
December 2009, she became a
Dispensing Practitioner under Florida
law, which authorized her to sell
medicinal drugs to patients in her office.
Id. at 60–61.
On April 30, 2010, DOH Investigators
went to the Mercy Wellness clinic to
conduct a dispensing practitioner
inspection; at the same time, the Ft.
Lauderdale Police Department executed
a search warrant at the clinic. GX 4, at
1. Upon their arrival, the DOH
Investigators observed that the clinic
had an armed security guard at both the
front and back entrances and that it had
‘‘a large waiting area filled with
patients.’’ GX 5, at 47.
DOH Investigators interviewed several
employees as well as Respondent.
According to an affidavit of one of the
DOH Investigators, at the time of the
inspection a different doctor, M.W., was
listed in DOH’s records as the
dispensing practitioner of record and
was ‘‘the intended subject of the
inspection.’’ GX 5, at 47. However, upon
arriving at the clinic, the Investigators
determined that Dr. M.W. had stopped
working there on April 2nd and that
Respondent ‘‘was the dispensing
practitioner.’’ Id.
According to the Investigator’s
affidavit, the clinic had ‘‘one
examination room and a room directly
adjacent to it which’’ was identified ‘‘as
the ‘Pharmacy.’’’ Id. The Pharmacy had
a ‘‘teller like window where the
prescription drug products [were]
dispensed and sold to the patient’’ and
the room was ‘‘accessible to all [clinic]
personnel.’’ Id. Inside the dispensing
room were two safes, one of which was
open and contained drugs; ‘‘[t]here were
also unlabeled bottles of prescription
drug products located on a table in the
[dispensing room] which [J.F., a
pharmacy technician] had been
PO 00000
Frm 00082
Fmt 4703
Sfmt 4703
preparing to be dispensed to patients.’’
Id. at 55. Inside the dispensing room,
the Investigators also observed R.H.,
who was printing out prescriptions from
the patient charts on a computer. Id. at
48.
During her interview, Respondent
‘‘admitted that she [did] not verify [or]
check the medications that [were]
dispensed and sold to any of the
patients’’ as this was done by J.F. Id.
While Respondent stated that she had
signed at least three order forms (DEA–
222) for schedule II controlled
substances, and admitted that she had
‘‘no knowledge of the amount of
prescription drug products [that were]
being ordered,’’ the forms were
completed by the pharmacy technician
and then signed by her. Id. at 52.
Respondent stated, however, that she
did not know ‘‘when or how often [the]
drugs [we]re delivered to the facility,’’
and ‘‘who receive[d] them.’’ Id. In
addition, Respondent did not know how
the invoices were paid or the
combination to the safe where the drugs
were stored.2 Id.
During her interview, Respondent
initially stated that J.F. was the
pharmacist and in charge of the
pharmacy. Id. at 61. However,
Respondent then acknowledged that J.F.
was only a pharmacy technician. Id.
The DOH Investigators further noted
that Dr. W. had left prescription drug
products at the clinic when he left its
employment and that these were
‘‘allegedly transferred to’’ Respondent.
Moreover, Respondent admitted that on
April 20, 2010, she signed a DEA 222
form to take possession of the controlled
substances left by Dr. W. Id. at 37.
However, according to a DOH
Investigator, ‘‘there was no
documentation to support that Dr. [W.]
authorized such a transaction either
personally or through power of
attorney.’’ Id. at 7. In addition, the DOH
Investigator determined that ‘‘DEA 222
forms revealed that C–II prescriptions
drugs were received between 04/02/10
2 Respondent also stated that she saw 60 to 65
patients a day, to whom she prescribed oxycodone
30mg and 15mg, muscle relaxants such as
carisoprodol, and Xanax (alprazolam), a
combination of drugs which this Agency has
encountered in investigations of physicians engaged
in blatant drug dealing. See, e.g., Paul H. Volkman,
73 FR 30630 (2008); GX 5, at 63–64 (Respondent’s
sworn statement to Investigators that she would
issue two to four prescriptions to a patient; ‘‘It is
a combination, anti-inflammatory, muscle relaxers,
pain killers. I really believe in them. You know the
combination is the key.’’). Yet the Government
made no allegation that Respondent issued
prescriptions outside of the usual course of
professional practice and lacking a legitimate
medical purpose, 21 CFR 1306.04(a), and produced
no evidence that any prescription she issued was
unlawful.
E:\FR\FM\01JYN1.SGM
01JYN1
mstockstill on DSK4VPTVN1PROD with NOTICES
Federal Register / Vol. 78, No. 126 / Monday, July 1, 2013 / Notices
and 04/13/10 at which time no licensed
practitioner was working who could
legally possess the prescription drugs.’’
Id. Moreover, because there were no
pedigree documents for any of the
drugs, the DOH Investigators
determined that the drugs were
adulterated under Florida law and
seized them in place. Id. at 9, 38.
According to various records, DOH
seized several thousand dosage units of
controlled substances including
oxycodone (in both 30mg and 15mg
strength), hydrocodone, alprazolam,
diazepam, as well as carisoprodol, a
drug which was then controlled under
Florida law but not Federal law. Id. at
69–72.
Respondent further admitted to a
DOH Investigator that she ‘‘never
completed an inventory of the
medication present and did not know of
any inventory ever [having been] taken
by others.’’ Id. at 38. Respondent also
told a DOH Investigator that she did not
‘‘know until today that [J.F.] was not a
pharmacist—[she] thought he was.’’ Id.
However, when the Investigator then
told Respondent that ‘‘an 8 c x 11
printout stating that [J.F.] is a Registered
Pharmacy Technician [was] on the wall
immediately inside her dispensing
room,’’ Respondent replied that she had
‘‘never been in that room.’’ Id.
During the inspection, Respondent
agreed to voluntarily surrender her DEA
registration. Respondent completed a
DEA Form 104 evidencing her
agreement. GX 5, at 67. On July 29,
2010, Respondent applied for a new
registration. GX 1.
As noted above, following service of
the Show Cause Order, Respondent
submitted an unsworn written statement
of position. GX 6. Therein, Respondent
stated that she had been placed at Mercy
by All Care Staffing, a temporary
staffing agency and had started work
there on April 13, 2010. GX 6, at 1.
Respondent further stated that she had
previously obtained work through All
Care and that at the time of her
placement at Mercy, she had
interviewed with two internal medicine
groups and while she was doing due
diligence on them, contacted All Care.
Id. According to Respondent, ‘‘All Care
assured [her] that [Mercy] was stable
and ran an above-board, legitimate,
compliant practice.’’ Id. Respondent
also stated that because her time at
Mercy ‘‘was the first time in [her]
professional career that [she] had been
a dispensing practitioner, [she] was
completely unaware that [she] had run
afoul of the laws governing dispensing
practitioners.’’ Id.
Respondent then addressed the
various violations found by the DOH
VerDate Mar<15>2010
21:38 Jun 28, 2013
Jkt 229001
Investigators. First, she asserted that
‘‘[t]o the best of [her] knowledge, the
prescription drugs at [Mercy] were at all
times stored and otherwise locked in a
safe . . . and that access was restricted,
in compliance with 21 CFR 1301.75.’’
Id. at 2. She asserted that when she
asked whether she should have the
safe’s combination, the owners told her
that this ‘‘was not a legal requirement’’
and that she ‘‘could inspect the safe at
any time.’’ Id. She also maintained that
she ‘‘believed that [Mercy] employed a
pharmacist who was responsible for and
addressed all pharmacy and
prescription issues’’ and that ‘‘[i]t
seemed reasonable . . . to rely upon the
owners of [Mercy] to employ properly
trained and credentialed personnel in
the pharmacy.’’ Id.
Respondent further stated that ‘‘upon
the initial date’’ of her employment at
Mercy, she ‘‘did order medications
pursuant to a form DEA 222’’ and did
so because she was told that she ‘‘could
not use the medications that had been
ordered by’’ Dr. W., the previous doctor.
Id. Respondent maintained that she
‘‘was provided with the DEA 222 form
by [clinic] personnel, but was
unfortunately unaware of my
obligations regarding the DEA 222 form
at the time.’’ Id. She then explained that
she ‘‘was informed that Dr. [W.] was
responsible for addressing the
medications that he left behind as well
as the DEA 222 forms associated with
him,’’ and therefore, she ‘‘did not
address them or to [her] knowledge
dispense any medications that had
previously been ordered by Dr. [W.]’’ Id.
However, Respondent then stated that
Mercy ‘‘refused to make Dr. [W.]
available to [her], so in hindsight,
proper transfer may not have been
possible.’’ Id.
Respondent stated that because she
‘‘worked three days a week for a three
week period of time, [she] did not do an
inspection or complete an inventory.’’
Id. She then stated that ‘‘no prior
inventories or logs were made available
to’’ her. Id.
Respondent ‘‘acknowledge[d] that
[she] did not personally check and
certify filled prescription[s] for accuracy
prior to [the] patient receiving’’ them.
Id. Respondent reiterated that she
‘‘believed that there was [a] pharmacist
employed at [Mercy] that ensured
compliance with these issues’’ and that
because of her belief, she ‘‘was not
always present when medications were
dispensed nor did I initial all
prescription labels.’’ Id. Regarding the
DOH report’s statement that she had
denied having been in the ‘‘Pharmacy’’
room, Respondent stated that she ‘‘had
been in the dispensing room and had
PO 00000
Frm 00083
Fmt 4703
Sfmt 4703
39333
seen the technician enter information
into the . . . computer system, prepare
labels, count pills and place them in
prescription bottles for dispensing.’’ Id.
She also stated that she is now aware
that she had ‘‘an obligation to verify that
the personnel where I was providing
services were properly licensed to
perform certain duties.’’ Id.
Respondent further stated that
following the inspection, she terminated
her employment at Mercy. However, she
again reiterated that she ‘‘was
improperly led to believe that [Mercy]
was properly running its practice, with
the appropriate personnel, licenses, and
permits,’’ and that the dispensing of
drugs was being ‘‘done properly and in
full compliance with the law’’ but that
she had concluded that the ‘‘many
compliance breaches in this matter
clearly existed long before [her] locum
tenens assignment to’’ Mercy. Id. at 2–
3. Respondent further stated that she
has ‘‘been practicing medicine for
twenty-five years, and prior to this, had
an unblemished record’’ and that ‘‘[t]he
inspection and [her] very brief
relationship with [Mercy] has been a
very painful and embarrassing learning
process for’’ her. Id. at 3. Respondent
also stated that the DOH ‘‘inspection
report evidences that [she] was not
evasive and fully answered all the
questions asked from the participants of
the inspection.’’ Id.
Respondent stated that she ‘‘believed
that it was not improper for [her] to
provide services [for Mercy] and that the
practice was operated appropriately’’
and that she ‘‘simply was not fully
aware of the obligations discussed in the
paragraphs above and believed [she]
was in compliance with the laws.’’ Id.
Finally, Respondent stated that ‘‘[t]his
was the first time in [her] professional
career that [she] had been a dispensing
practitioner and [that she is] not
interested in dispensing again after the
experience [she] had with’’ Mercy. Id.
Discussion
Section 303(f) of the Controlled
Substances Act (CSA) provides that an
application for a practitioner’s
registration may be denied upon a
determination ‘‘that the issuance of such
registration . . . would be inconsistent
with the public interest.’’ 21 U.S.C.
823(f). In making the public interest
determination in the case of a
practitioner, Congress directed that the
following factors be considered:
(1) The recommendation of the appropriate
State licensing board or professional
disciplinary authority.
(2) The applicant’s experience in
dispensing . . . controlled substances.
E:\FR\FM\01JYN1.SGM
01JYN1
39334
Federal Register / Vol. 78, No. 126 / Monday, July 1, 2013 / Notices
(3) The applicant’s conviction record under
Federal or State laws relating to the
manufacture, distribution, or dispensing of
controlled substances.
(4) Compliance with applicable State,
Federal, or local laws relating to controlled
substances.
(5) Such other conduct which may threaten
the public health and safety.
mstockstill on DSK4VPTVN1PROD with NOTICES
Id.
‘‘[T]hese factors are considered in the
disjunctive.’’ Robert A. Leslie, 68 FR
15227, 15230 (2003). I may rely on any
one or a combination of factors and may
give each factor the weight I deem
appropriate in determining whether to
deny an application. Id. Moreover, I am
‘‘not required to make findings as to all
of the factors.’’ Hoxie v. DEA, 419 F.3d
477, 482 (6th Cir. 2005) (citing Morall v.
DEA, 412 F.3d 165, 173–74 (D.C. Cir.
2005)).
In the case of a practitioner, the
Government has the burden of proving
with substantial evidence that granting
an application would be inconsistent
with the public interest. However,
where the Government makes out a
prima facie case to deny an application,
the burden shifts to the applicant to
show why granting the application
would be consistent with the public
interest.3
In this matter, I conclude that the
Government’s evidence with respect to
factors four and five establishes a prima
facie case to deny Respondent’s
application.4 While I have considered
3 Where, as here, ‘‘the Government has proved
that a registrant has committed acts inconsistent
with the public interest, a registrant must ‘‘‘present
sufficient mitigating evidence to assure the
Administrator that [he] can be entrusted with the
responsibility carried by such a registration.’’’’’
Medicine Shoppe-Jonesborough, 73 FR 364, 387
(2008) (quoting Samuel S. Jackson, 72 FR 23848,
23853 (2007) (quoting Leo R. Miller, 53 FR 21931,
21932 (1988))), aff’d, Medicine ShoppeJonesborough v. DEA, 300 Fed. Appx. 409 (6th Cir.
2008). ‘‘Moreover, because ‘past performance is the
best predictor of future performance,’ ALRA Labs,
Inc. v. DEA, 54 F.3d 450, 452 (7th Cir. 1995), [DEA]
has repeatedly held that where a registrant has
committed acts inconsistent with the public
interest, the registrant must accept responsibility for
[his] actions and demonstrate that [he] will not
engage in future misconduct.’’ Medicine Shoppe, 73
FR at 387; accord Jackson, 72 FR at 23853; John H.
Kennedy, 71 FR 35705, 35709 (2006); Prince George
Daniels, 60 FR 62884, 62887 (1995). See also Hoxie
v. DEA, 419 F.3d at 483 (‘‘admitting fault’’ is
‘‘properly consider[ed]’’ by DEA to be an
‘‘important factor[]’’ in the public interest
determination).
In addition, ‘‘DEA properly considers the candor
of the physician and his forthrightness in assisting
in the investigation and admitting fault important
factors in determining whether the physician’s
registration’’ is consistent with the public interest.’’
Hoxie, 419 F.3d at 483.
4 The only evidence in the record as to factor one
(the recommendation of the state licensing board)
is the approximately one year old DOH report
which shows that Respondent still had a state
license at that time. However, DEA has repeatedly
VerDate Mar<15>2010
21:38 Jun 28, 2013
Jkt 229001
Respondent’s statement of position, I
conclude that she has not provided
substantial evidence to show why, at
this time, she can be entrusted with a
new registration.
Factors Four and Five—Compliance
With Applicable Laws Related to
Controlled Substances and Other
Conduct Which May Threaten Public
Health and Safety
Based on the DOH Inspection, the
Government alleges that Respondent
committed multiple violations of the
CSA, its implementing regulations, as
well as Florida law and regulations.
These violations include her failure to
conduct an initial inventory of the
controlled substances, her failure to
institute sufficient security/diversion
controls, and her improper execution of
a DEA 222 form for the transfer of
controlled substances from the clinic’s
prior doctor.
The CSA provides in relevant part
that ‘‘every registrant . . . shall . . . as
soon . . . as such registrant first engages
in the manufacture, distribution, or
dispensing of controlled substances . . .
make a complete and accurate record of
all stocks thereof on hand.’’ 21 U.S.C.
827(a)(1).5 Respondent acknowledged
that she failed to comply with this
provision. This was also a violation of
Florida law. See Fla. Stat. Ann.
§ 893.07(1)(a).
The Government further argues that
Respondent ‘‘could not specify what
quantity of drugs she received from Dr.
[W.’s] stock of controlled substances,
thus violating 21 CFR 1304.22.’’ Req. for
Final Agency Action, at 5. This,
however, is simply the same violation as
set forth in the preceding paragraph.6
held that while the possession of state licensure is
a fundamental condition for obtaining and
maintaining a practitioner’s registration, it is not
dispositive of the public interest inquiry.
As for factor three, the Government raises no
contention that Respondent has been convicted of
a federal or state law offense related to controlled
substances. However, because there are multiple
reasons why an applicant or registrant may not have
been convicted or even prosecuted for such an
offense, the absence of such a conviction ‘‘is of
considerably less consequence in the public interest
inquiry.’’ Dewey C. MacKay, 75 FR 49956, 49973
(2010), pet. for rev. denied 2011 WL 6739420 (10th
Cir., Dec. 23, 2011). See also Jayam Krishna-Iyer, 74
FR at 459, 461 (2009); Edmund Chein, 72 FR 6580,
6593 n.22 (2007), pet. for rev. denied 533 F.3d 828
(DC Cir. 2008). Accordingly, this factor is not
dispositive.
5 While the CSA exempts from the recordkeeping
requirements ‘‘the prescribing of controlled
substances . . . by practitioners acting in the lawful
course of professional practice unless such
substance is prescribed in the course of
maintenance or detoxification treatment of an
individual,’’ 21 U.S.C. 827(c)(1)(A), the evidence
shows that Respondent was not only prescribing
but also dispensing controlled substances.
6 The Government also alleges that Respondent
violated Federal law when she ‘‘signed a DEA Form
PO 00000
Frm 00084
Fmt 4703
Sfmt 4703
The Government also contends that
Respondent violated Federal regulations
because she allowed other persons to
order controlled substances on her
behalf and did not issue a Power of
Attorney. The Government argues that
although Respondent signed several
Schedule II order forms which were
‘‘completed by another individual, she
did not order the medications and she
was not notified when controlled
substances were ordered on her behalf.’’
Id. at 5; see also Show Cause Order ¶
2d (citing 21 CFR 1305.05(a)). As found
above, Respondent admitted that she
did not know the amount of the drugs
that were being ordered under her
registration. Yet other evidence
establishes that the DEA 222 forms were
completed by the pharmacy technician
and then signed by Respondent.
Under the CSA, a schedule II
controlled substance can only be
distributed pursuant to ‘‘a written order
of the person to whom such substance
is distributed, made on a form . . .
issued by the Attorney General [DEA–
222].’’ 21 U.S.C. 828(a). DEA regulations
further provide, in relevant part, that
‘‘[o]nly persons who are registered . . .
under section 303 of the [CSA] to
handle Schedule I or II controlled
substances . . . may obtain and used
DEA Form 222 . . . for these
substances. Persons not registered to
handle Schedule I or II controlled
substances . . . are not entitled to
obtain Form 222.’’ 21 CFR 1305.04(a). A
registrant may, however, ‘‘authorize one
or more individuals . . . to issue orders
for Schedule I and II controlled
substances on the registrant’s behalf by
executing a power of attorney for each
such individual.’’ Id. 1305.05(a).
The evidence does not, however,
establish that Respondent violated
either the CSA or the Agency’s
regulations by signing the order forms
because the evidence shows that the
forms were completed by the pharmacy
technician and then signed by
Respondent. Thus, because Respondent
signed the form, she and not the
pharmacy technician issued the orders,
222 to take possession of controlled substances that
were abandoned by a former practitioner at the
clinic.’’ Show Cause Order at 2. As noted above, in
an affidavit, a DOH Investigator stated that ‘‘there
was no documentation to support that Dr. [W.]
authorized such a transaction either personally or
through [a] power of attorney.’’ GX 5, at 53. Given
the Government’s assertion that the drugs ‘‘were
abandoned,’’ it is not clear why it was necessary for
Dr. W. to authorize the transaction and why
Respondent violated Federal law by signing a Form
222. The Government makes no further argument
that it was unlawful for Respondent to acquire
possession of the controlled substances that were at
the clinic when she commenced her employment
there because the clinic owners were not registered
and could not lawfully distribute the drugs to her.
E:\FR\FM\01JYN1.SGM
01JYN1
mstockstill on DSK4VPTVN1PROD with NOTICES
Federal Register / Vol. 78, No. 126 / Monday, July 1, 2013 / Notices
and Respondent was not required to
execute a power of attorney form.
However, Respondent admitted that
she did not know what controlled
substances were being ordered under
her registration as well as when they
were being received, and the evidence
shows that other scheduled drugs
including hydrocodone, alprazolam,
and diazepam (which do not require the
execution of a Form 222 to order) were
found at the clinic. Moreover, other
evidence establishes that the clinic did
dispense controlled substances
(notwithstanding that Respondent had
been at the clinic for only seventeen
days at the time of the inspection)
which were ordered under her
registration. Under DEA’s regulations
applicable to all registrants, a
practitioner is required to institute and
maintain an adequate system ‘‘for
monitoring the receipt . . . distribution,
and disposition of controlled
substances.’’ 21 CFR 1301.71(b)(14).
Respondent did not comply with this
requirement.
The CSA also requires that ‘‘every
registrant . . . manufacturing,
distributing, or dispensing a controlled
substance or substances shall maintain,
on a current basis, a complete and
accurate record of each such substance
manufactured, received, sold, delivered,
or otherwise disposed of by him.’’ Id.
§ 827(a)(3). Florida law imposes a
similar obligation on persons engaged in
the dispensing of controlled substances.
See Fla. Stat. Ann. § 893.07(b).
However, the record does not establish
whether the clinic was maintaining the
invoices documenting the receipt of
controlled substances or a proper
dispensing log.
The Government also alleges that
‘‘Respondent failed to store [the]
controlled substances in a securely
locked cabinet’’ and that DOH
Investigators observed that multiple
employees had access to the drug
dispensing room. Req. for Final Agency
Action, at 4 (citing 21 CFR
1301.71(b)(11) and 1301.75(b)). As for
the failure to store the controlled
substances in a securely locked cabinet,
the DOH Investigators stated that drugs
were observed both in an open safe and
on a table in the pharmacy area. It is not
clear why this would constitute a
violation if the clinic was then open and
preparing prescriptions for dispensing.
As for the observation that multiple
employees had access to the dispensing
room, under DEA regulations, ‘‘[a]ll
applicants and registrants shall provide
effective controls and procedures to
guard against theft and diversion of
controlled substances.’’ 21 CFR
1301.71(a). Among the factors which
VerDate Mar<15>2010
21:38 Jun 28, 2013
Jkt 229001
DEA considers is ‘‘[t]he adequacy of
supervision over employees having
access to manufacturing and storage
areas.’’ Id. at 1301.71(b)(11) (emphasis
added). While the affidavits state that
multiple employees had access to the
dispensing room, the record is devoid of
evidence establishing whether the
supervision of these employees was
adequate.7
The evidence also shows that clinic
personnel (including Respondent)
violated various provisions of State law.
More specifically, the evidence showed
that the clinic employee who filled the
prescriptions and dispensed them was
not licensed as a pharmacist, but rather
only as a pharmacy technician, and that
Respondent, who was registered as a
dispensing physician, admitted that she
did not verify the prescriptions that
were dispensed to the patients. Under
Florida law in effect at the time of the
events at issue here, ‘‘[a] person may not
dispense medicinal drugs unless
licensed as a pharmacist or otherwise
authorized under this chapter to do so,
except that a practitioner authorized by
law to prescribe drugs may dispense
such drugs to her or his patients in the
regular course of her or his practice in
compliance with this section.’’ Fla. Stat.
§ 465.0276(1).8 See also Fla. Admin.
Code r.64B16–27.1001(3) (‘‘Only a
pharmacist may make the final check of
the completed prescription thereby
assuming the complete responsibility
for its preparation and accuracy.’’).
In her written statement, Respondent
repeatedly asserted that she believed
that the pharmacy technician was
actually a licensed pharmacist. I do not
find this credible because the affidavit
of one of the DOH Investigators
establishes that ‘‘on the wall
immediately inside the dispensing
room,’’ there was an 81⁄2 by 11 printout
7 Agency regulations explicitly require that nonpractitioner registrants limit access to storage areas.
See 21 CFR 1301.72(d) (security requirements for
non-practitioners; ‘‘The controlled substances
storage areas shall be accessible only to an absolute
minimum number of specifically authorized
employees.’’). There is, however, no similar
requirement applicable to practitioners.
8 In addition, under Florida law, ‘‘[a] person other
than a licensed pharmacist or pharmacy intern may
not engage in the practice of the profession of
pharmacy, except that a licensed pharmacist may
delegate to pharmacy technicians who are
registered pursuant to this section duties, tasks, and
functions that do not fall within the purview of s.
465.003(13).’’ Fla. Stat. § 465.014(1). However, ‘‘[a]ll
such delegated acts shall be performed under the
direct supervision of a licensed pharmacist who
shall be responsible for all such acts performed by
persons under his or her supervision.’’ Id. A
dispensing practitioner ‘‘must . . . [c]omply with
and be subject to all laws and rules applicable to
pharmacists and pharmacies, including, but not
limited to’’ chapter 465, which regulates the
practice of pharmacy. Id. § 465.0276(2)(b).
PO 00000
Frm 00085
Fmt 4703
Sfmt 4703
39335
stating that the employee who did the
dispensing was a Registered Pharmacy
Technician. See also Fla. Admin. Code
r.64B16–27.100(4) (‘‘The current
registration of each registered pharmacy
technician shall be displayed, when
applicable, in a conspicuous place in or
near the prescription department, and in
such a manner that can be easily read
by patrons of said establishment.’’). In
his affidavit, the Investigator further
stated that when Respondent said that
she did not ‘‘know until today that [J.F.]
was not a pharmacist,’’ he confronted
her with the information regarding the
printout, to which Respondent replied
that she had ‘‘never been in that room.’’
However, in her written statement,
Respondent stated that she had been in
the dispensing room and seen the
technician prepare the labels, count the
pills and place them in the bottles for
dispensing. Unexplained by Respondent
is how she could then have been
unaware that J.F. was not a licensed
pharmacist. I thus reject Respondent’s
contention that she believed that J.F.
was a pharmacist and could lawfully
dispense medications. Moreover, it is a
violation of the Florida Medical Practice
Act to ‘‘delegat[e] professional
responsibilities to a person when the
licensee delegating such responsibilities
knows or has reason to know that such
person is not qualified by training,
experience, or licensure to perform
them.’’ Fla. Stat. Ann. § 458.331(w).
The DOH Investigators further found
that the clinic did not have pedigree
documents for any of the drugs that
were on hand. As noted above,
Respondent admitted that drugs were
ordered under her DEA registration
during her time there. Florida law
provides in relevant part that ‘‘[a] drug
or device is adulterated . . . [i]f it is a
prescription drug for which the required
pedigree paper 9 is nonexistent.’’ Id.
§ 499.006(10). Moreover, under state
regulations, ‘‘[a] copy of the pedigree
paper must be maintained by each
recipient,’’ Fla. Admin Code r. 64F–
12.012(3)(d), and for a ‘‘permittee[]
located in the state . . . must be readily
available and immediately retrievable,
i.e., subject to inspection at the
9 The pedigree paper ‘‘must include either the
proprietary name or generic name with the name of
the manufacturer, repackager, or distributor as
reflected on the label of the product; dosage form;
strength; container size; quantity by lot number; the
name and address of each owner of the prescription
drug that is required to be identified on the
pedigree paper; the name and address of each
location from which it was shipped if different from
the owner’s; and the transaction dates.’’ Fla. Admin
Code r. 64F–12.012(3)(a)1. In addition, ‘‘[t]he
pedigree paper must clearly identify the invoice to
which it relate[s].’’ Id.
E:\FR\FM\01JYN1.SGM
01JYN1
39336
Federal Register / Vol. 78, No. 126 / Monday, July 1, 2013 / Notices
mstockstill on DSK4VPTVN1PROD with NOTICES
permitted establishment during the
inspection.’’ Id. r.64F–12.012(6)(b).
As the forgoing demonstrates,
Respondent failed to comply with a
variety of federal and state controlled
substance laws and regulations as well
as state pharmacy laws and rules. As for
the latter, while these laws and rules are
applicable to all prescription drugs and
not just controlled substances, these
violations are properly considered
under factor five as other conduct which
may threaten public health and safety
for two reasons. First, the violations
involved the dispensing of controlled
substances. Second, violations of state
pharmacy rules and food and drug
safety provisions are relevant (even if
the conduct did not involve controlled
substances) in assessing the likelihood
of an applicant’s future compliance with
the CSA. See Paul Weir Battershell, 76
FR 44359, 44368 (2011); Wonderyears,
Inc., 74 FR 457, 458 n.2 (2009).
On the other hand, the record in this
matter establishes that Respondent’s
record of non-compliance with the CSA
was limited to a seventeen-day period.
While it may be that this conduct would
have continued but for the DOH
inspection, Respondent stated in her
letter that following the inspection she
terminated her relationship at the clinic
and there is no evidence disputing
this.10
It is also acknowledged that
Respondent’s letter demonstrated some
degree of contrition. However, I do not
find credible Respondent’s numerous
assertions that she believed that JF was
a licensed pharmacist. In addition,
while Respondent emphasizes that her
employment at Mercy ‘‘was the first
time in [her] professional career that
[she] had been a dispensing
practitioner,’’ and that she ‘‘was
completely unaware that [she] had run
afoul of the laws governing dispensing
practitioners,’’ GX 6, at 1, ignorance of
the law is no excuse. See Patrick W.
Stodola, 74 FR 20727, 20735 (2009)
(quoting Hageseth v. Superior Ct., 59
Cal. Rptr.3d 385, 403 (Ct. App. 2007) (a
‘‘licensed health care provider cannot
‘reasonably claim ignorance’ of state
provisions regulating medical
practice’’)). Indeed, in her statement,
Respondent explained that at the time
she took her position, she ‘‘was doing
10 Hanging over this matter is the dark cloud of
evidence that Mercy was a pain clinic and that
Respondent was seeing some 60 to 65 patients a day
to whom she was prescribing such drugs as
oxycodone 30mg and 15mg, muscle relaxants such
as carisoprodol, and Xanax (alprazolam). However,
evidence which creates only a suspicion of
wrongdoing does not constitute substantial
evidence. See NLRB v. Columbian Enameling &
Stamping Co., Inc., 306 U.S. 292, 299–300 (1939).
I therefore do not rely on it.
VerDate Mar<15>2010
21:38 Jun 28, 2013
Jkt 229001
due diligence’’ on two internal medicine
groups. One must wonder why she did
not make a similar effort to familiarize
herself with the various requirements
applicable to the dispensing of
controlled substances under both the
CSA and state laws, as well as the
manner in which Mercy’s business was
operated.
DEA can, of course, consider
deterrence interests in determining
whether to grant or deny an application.
See Joseph Gaudio, 74 FR 10083, 10094
(2009) (citing Southwood
Pharmaceuticals, Inc., 72 FR 36487,
36504 (2007)). As I have previously
explained, ‘‘‘even when a proceeding
serves a remedial purpose, an
administrative agency can properly
consider the need to deter others from
engaging in similar acts.’’’ Gaudio, 74
FR at 10094 (quoting Southwood, 72 FR
at 36504 (citing Butz v. Glover Livestock
Commission Co., Inc., 411 U.S. 182,
187–88 (1973)). ‘‘The ‘[c]onsideration of
the deterrent effect of a potential
sanction is supported by the CSA’s
purpose of protecting the public
interest,’’’ which is manifested in both
21 U.S.C. 823(f) and 824(a)(4). Gaudio,
74 FR at 10094 (quoting 72 FR at 36504).
All registrants are charged with
knowledge of the CSA, its implementing
regulations, as well as applicable state
laws and rules. Moreover, those
registrants who contemplate
employment in circumstances in which
their registrations are used to operate
clinics owned by non-registrants need to
recognize that there are serious
consequences for failing to comply with
the Act and that they remain strictly
liable for all activities which occur
under the authority of their
registrations. See, e.g., Robert Raymond
Reppy, 76 FR 61154, 61157–58 (2011);
Paul Weir Battershell, 76 FR 44359,
44368 (2011); Paul Volkman, 73 FR
30630, 30643–44 (2008), pet. for rev.
denied 567 F.3d 215 (6th Cir. 2009). It
is no excuse that the practitioner is not
the employer of those persons who
perform controlled substance activities
and lacks the power to hire or fire the
employee.
Accordingly, having considered the
record as a whole, I conclude that
Respondent has not sufficiently
demonstrated why she should be
entrusted with a new registration. I
therefore hold that granting
Respondent’s application would, at this
time, be ‘‘inconsistent with the public
interest.’’ 21 U.S.C. 823(f). However,
given that the violations proved on this
record were limited in both their scope
and duration, a new application should
be given favorable consideration if
submitted no earlier than one year from
PO 00000
Frm 00086
Fmt 4703
Sfmt 4703
the date of this Order, provided that
Respondent meets the following
conditions: (1) That she does not engage
in any further misconduct, and (2) that
she takes a certified Continuing Medical
Education course on controlled
substance handling and dispensing.
Order
Pursuant to the authority vested in me
by 21 U.S.C. 823(f) and 28 CFR 0.100(b),
I order that the application of Sigrid
Sanchez, M.D., for a DEA Certificate of
Registration as a practitioner, be, and it
hereby is, denied. This order is effective
July 31, 2013
Dated: June 20, 2013.
Michele M. Leonhart,
Administrator.
[FR Doc. 2013–15706 Filed 6–28–13; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Application; Mylan
Pharmaceuticals, Inc.
Pursuant to Title 21 Code of Federal
Regulations 1301.34 (a), this is notice
that on March 8, 2013, Mylan
Pharmaceuticals, Inc., 3711 Collins
Ferry Road, Morgantown, West Virginia
26505, made application to the Drug
Enforcement Administration (DEA) to
be registered as an importer of the
following basic classes of controlled
substances:
Drug
Amphetamine (1100) ....................
Lisdexamfetamine (1205) .............
Methylphenidate (1724) ................
Pentobarbital (2270) .....................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Hydrocodone (9193) .....................
Levorphanol (9220) ......................
Morphine (9300) ...........................
Oxymorphone (9652) ...................
Remifentanil (9739) ......................
Fentanyl (9801) ............................
Schedule
II
II
II
II
II
II
II
II
II
II
II
II
The company plans to import the
listed controlled substances in finished
dosage form (FDF) from foreign sources
for analytical testing and clinical trials
in which the foreign FDF will be
compared to the company’s own
domestically-manufactured FDF. This
analysis is required to allow the
company to export domesticallymanufactured FDF to foreign markets.
Any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic classes of controlled
E:\FR\FM\01JYN1.SGM
01JYN1
Agencies
[Federal Register Volume 78, Number 126 (Monday, July 1, 2013)]
[Notices]
[Pages 39331-39336]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-15706]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Sigrid Sanchez, M.D.; Decision and Order
On February 4, 2011, the Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement Administration, issued an Order to
Show Cause to Sigrid A. Sanchez, M.D. (Respondent), of Sunrise,
Florida. The Show Cause Order proposed the denial of Respondent's
pending application for a DEA Certificate of Registration as a
practitioner, on the ground that her ``registration would be
inconsistent with the public interest.'' GX 7, at 1 (citing 21 U.S.C.
823(f)).
More specifically, the Show Cause Order alleged that on May 19,
2010, Respondent had surrendered her previous DEA registration, and
that on July 29, 2010, she had applied for a new registration. Id. The
Show Cause Order further alleged that on April 30, 2010, the Florida
Department of Health had conducted ``a dispensing practitioner's
[[Page 39332]]
inspection'' at Respondent's former registered location, the Mercy
Wellness and Recovery Center of Fort Lauderdale, Florida, finding
violations of both federal and state law. Id.
The Order alleged that the federal violations included, inter alia,
failing to provide adequate supervision over employees who had access
to controlled-substance storage areas, failing to store controlled
substances in a securely locked cabinet, taking possession of
controlled substances at the clinic upon commencing her employment
while failing to conduct an inventory of the controlled substances,
failing to supervise the dispensing of controlled substances by clinic
employees, authorizing an employee to order schedule II controlled
substances without executing a Power of Attorney, and not having ``an
adequate system for monitoring the receipt, distribution and
disposition of controlled substances.'' Id. at 1-2 (citing 21 CFR
1301.71(a), (b)(11), (b)(14); 1301.75(b); 1304.21(a); 1304.22).
With respect to the state violations, the Show Cause Order alleged
that ``by the transfer of controlled substances,'' Respondent violated
various provisions of Floria law. Id. at 2 (citing Fla. Stat. Ann.
Sec. Sec. 499.0051(1), 499.006(10), and 499.0121(6) (all 2010)). The
Order also alleged that Respondent's ``failure to supervise and review
the dispensing of controlled substances'' violated both Florida
statutes and regulations. Id. (citing Fla. Stat. Ann. Sec.
893.04(1)(b) (2010); Fla. Admin. Code Ann. r. 64B16-27.1001(3) & (4)
(2010); id. r. 64B16-28.140(3) (2010)). Finally, the Show Cause Order
alleged that Respondent also violated state controlled substance
recordkeeping requirements. Id. (citing Fla. Stat. Ann. Sec. Sec.
893.07(1)(a) & (b); 893.07(2)).\1\
---------------------------------------------------------------------------
\1\ The Show Cause Order also notified Respondent of her right
to request a hearing on the allegations or to submit a written
statement in lieu of a hearing, the procedures for electing either
option, and the consequences for failing to do so. GX 7, at 3.
---------------------------------------------------------------------------
In a letter dated February 16, 2011, Respondent acknowledged
service of the Show Cause Order. In her letter, Respondent further
stated that she was waiving her right to a hearing but submitting a
``written statement regarding [her] position on the matters of fact and
law involved.'' GX 6. See also 21 CFR 1301.43(c). Respondent's
statement was made a part of the record. See GX 6. On September 20,
2011, the record was forwarded to my Office for Final Agency Action.
Having considered the entire record (including Respondent's
statement), I conclude that granting Respondent's application would be
inconsistent with the public interest. Accordingly, Respondent's
application will be denied. I make the following findings.
Findings
Respondent previously held a DEA Certificate of Registration as a
practitioner in schedules II through V. GX 1, at 1. On April 7, 2010,
Respondent changed her registered address to 2001 N E 48th St., Fort
Lauderdale, Florida. Id. This address was the location of the Mercy
Wellness and Recovery Center (hereinafter, Mercy), a pain management
clinic. GX 5, at 59. On or about April 13, 2010, Respondent, who is
board certified in internal medicine, became the clinic's medical
doctor. Id. at 1, 48, 60. According to a sworn statement Respondent
gave to Investigators of the Florida Department of Health (DOH), in
December 2009, she became a Dispensing Practitioner under Florida law,
which authorized her to sell medicinal drugs to patients in her office.
Id. at 60-61.
On April 30, 2010, DOH Investigators went to the Mercy Wellness
clinic to conduct a dispensing practitioner inspection; at the same
time, the Ft. Lauderdale Police Department executed a search warrant at
the clinic. GX 4, at 1. Upon their arrival, the DOH Investigators
observed that the clinic had an armed security guard at both the front
and back entrances and that it had ``a large waiting area filled with
patients.'' GX 5, at 47.
DOH Investigators interviewed several employees as well as
Respondent. According to an affidavit of one of the DOH Investigators,
at the time of the inspection a different doctor, M.W., was listed in
DOH's records as the dispensing practitioner of record and was ``the
intended subject of the inspection.'' GX 5, at 47. However, upon
arriving at the clinic, the Investigators determined that Dr. M.W. had
stopped working there on April 2nd and that Respondent ``was the
dispensing practitioner.'' Id.
According to the Investigator's affidavit, the clinic had ``one
examination room and a room directly adjacent to it which'' was
identified ``as the `Pharmacy.''' Id. The Pharmacy had a ``teller like
window where the prescription drug products [were] dispensed and sold
to the patient'' and the room was ``accessible to all [clinic]
personnel.'' Id. Inside the dispensing room were two safes, one of
which was open and contained drugs; ``[t]here were also unlabeled
bottles of prescription drug products located on a table in the
[dispensing room] which [J.F., a pharmacy technician] had been
preparing to be dispensed to patients.'' Id. at 55. Inside the
dispensing room, the Investigators also observed R.H., who was printing
out prescriptions from the patient charts on a computer. Id. at 48.
During her interview, Respondent ``admitted that she [did] not
verify [or] check the medications that [were] dispensed and sold to any
of the patients'' as this was done by J.F. Id. While Respondent stated
that she had signed at least three order forms (DEA-222) for schedule
II controlled substances, and admitted that she had ``no knowledge of
the amount of prescription drug products [that were] being ordered,''
the forms were completed by the pharmacy technician and then signed by
her. Id. at 52. Respondent stated, however, that she did not know
``when or how often [the] drugs [we]re delivered to the facility,'' and
``who receive[d] them.'' Id. In addition, Respondent did not know how
the invoices were paid or the combination to the safe where the drugs
were stored.\2\ Id.
---------------------------------------------------------------------------
\2\ Respondent also stated that she saw 60 to 65 patients a day,
to whom she prescribed oxycodone 30mg and 15mg, muscle relaxants
such as carisoprodol, and Xanax (alprazolam), a combination of drugs
which this Agency has encountered in investigations of physicians
engaged in blatant drug dealing. See, e.g., Paul H. Volkman, 73 FR
30630 (2008); GX 5, at 63-64 (Respondent's sworn statement to
Investigators that she would issue two to four prescriptions to a
patient; ``It is a combination, anti-inflammatory, muscle relaxers,
pain killers. I really believe in them. You know the combination is
the key.''). Yet the Government made no allegation that Respondent
issued prescriptions outside of the usual course of professional
practice and lacking a legitimate medical purpose, 21 CFR
1306.04(a), and produced no evidence that any prescription she
issued was unlawful.
---------------------------------------------------------------------------
During her interview, Respondent initially stated that J.F. was the
pharmacist and in charge of the pharmacy. Id. at 61. However,
Respondent then acknowledged that J.F. was only a pharmacy technician.
Id.
The DOH Investigators further noted that Dr. W. had left
prescription drug products at the clinic when he left its employment
and that these were ``allegedly transferred to'' Respondent. Moreover,
Respondent admitted that on April 20, 2010, she signed a DEA 222 form
to take possession of the controlled substances left by Dr. W. Id. at
37. However, according to a DOH Investigator, ``there was no
documentation to support that Dr. [W.] authorized such a transaction
either personally or through power of attorney.'' Id. at 7. In
addition, the DOH Investigator determined that ``DEA 222 forms revealed
that C-II prescriptions drugs were received between 04/02/10
[[Page 39333]]
and 04/13/10 at which time no licensed practitioner was working who
could legally possess the prescription drugs.'' Id. Moreover, because
there were no pedigree documents for any of the drugs, the DOH
Investigators determined that the drugs were adulterated under Florida
law and seized them in place. Id. at 9, 38. According to various
records, DOH seized several thousand dosage units of controlled
substances including oxycodone (in both 30mg and 15mg strength),
hydrocodone, alprazolam, diazepam, as well as carisoprodol, a drug
which was then controlled under Florida law but not Federal law. Id. at
69-72.
Respondent further admitted to a DOH Investigator that she ``never
completed an inventory of the medication present and did not know of
any inventory ever [having been] taken by others.'' Id. at 38.
Respondent also told a DOH Investigator that she did not ``know until
today that [J.F.] was not a pharmacist--[she] thought he was.'' Id.
However, when the Investigator then told Respondent that ``an 8
[frac12] x 11 printout stating that [J.F.] is a Registered Pharmacy
Technician [was] on the wall immediately inside her dispensing room,''
Respondent replied that she had ``never been in that room.'' Id.
During the inspection, Respondent agreed to voluntarily surrender
her DEA registration. Respondent completed a DEA Form 104 evidencing
her agreement. GX 5, at 67. On July 29, 2010, Respondent applied for a
new registration. GX 1.
As noted above, following service of the Show Cause Order,
Respondent submitted an unsworn written statement of position. GX 6.
Therein, Respondent stated that she had been placed at Mercy by All
Care Staffing, a temporary staffing agency and had started work there
on April 13, 2010. GX 6, at 1. Respondent further stated that she had
previously obtained work through All Care and that at the time of her
placement at Mercy, she had interviewed with two internal medicine
groups and while she was doing due diligence on them, contacted All
Care. Id. According to Respondent, ``All Care assured [her] that
[Mercy] was stable and ran an above-board, legitimate, compliant
practice.'' Id. Respondent also stated that because her time at Mercy
``was the first time in [her] professional career that [she] had been a
dispensing practitioner, [she] was completely unaware that [she] had
run afoul of the laws governing dispensing practitioners.'' Id.
Respondent then addressed the various violations found by the DOH
Investigators. First, she asserted that ``[t]o the best of [her]
knowledge, the prescription drugs at [Mercy] were at all times stored
and otherwise locked in a safe . . . and that access was restricted, in
compliance with 21 CFR 1301.75.'' Id. at 2. She asserted that when she
asked whether she should have the safe's combination, the owners told
her that this ``was not a legal requirement'' and that she ``could
inspect the safe at any time.'' Id. She also maintained that she
``believed that [Mercy] employed a pharmacist who was responsible for
and addressed all pharmacy and prescription issues'' and that ``[i]t
seemed reasonable . . . to rely upon the owners of [Mercy] to employ
properly trained and credentialed personnel in the pharmacy.'' Id.
Respondent further stated that ``upon the initial date'' of her
employment at Mercy, she ``did order medications pursuant to a form DEA
222'' and did so because she was told that she ``could not use the
medications that had been ordered by'' Dr. W., the previous doctor. Id.
Respondent maintained that she ``was provided with the DEA 222 form by
[clinic] personnel, but was unfortunately unaware of my obligations
regarding the DEA 222 form at the time.'' Id. She then explained that
she ``was informed that Dr. [W.] was responsible for addressing the
medications that he left behind as well as the DEA 222 forms associated
with him,'' and therefore, she ``did not address them or to [her]
knowledge dispense any medications that had previously been ordered by
Dr. [W.]'' Id. However, Respondent then stated that Mercy ``refused to
make Dr. [W.] available to [her], so in hindsight, proper transfer may
not have been possible.'' Id.
Respondent stated that because she ``worked three days a week for a
three week period of time, [she] did not do an inspection or complete
an inventory.'' Id. She then stated that ``no prior inventories or logs
were made available to'' her. Id.
Respondent ``acknowledge[d] that [she] did not personally check and
certify filled prescription[s] for accuracy prior to [the] patient
receiving'' them. Id. Respondent reiterated that she ``believed that
there was [a] pharmacist employed at [Mercy] that ensured compliance
with these issues'' and that because of her belief, she ``was not
always present when medications were dispensed nor did I initial all
prescription labels.'' Id. Regarding the DOH report's statement that
she had denied having been in the ``Pharmacy'' room, Respondent stated
that she ``had been in the dispensing room and had seen the technician
enter information into the . . . computer system, prepare labels, count
pills and place them in prescription bottles for dispensing.'' Id. She
also stated that she is now aware that she had ``an obligation to
verify that the personnel where I was providing services were properly
licensed to perform certain duties.'' Id.
Respondent further stated that following the inspection, she
terminated her employment at Mercy. However, she again reiterated that
she ``was improperly led to believe that [Mercy] was properly running
its practice, with the appropriate personnel, licenses, and permits,''
and that the dispensing of drugs was being ``done properly and in full
compliance with the law'' but that she had concluded that the ``many
compliance breaches in this matter clearly existed long before [her]
locum tenens assignment to'' Mercy. Id. at 2-3. Respondent further
stated that she has ``been practicing medicine for twenty-five years,
and prior to this, had an unblemished record'' and that ``[t]he
inspection and [her] very brief relationship with [Mercy] has been a
very painful and embarrassing learning process for'' her. Id. at 3.
Respondent also stated that the DOH ``inspection report evidences that
[she] was not evasive and fully answered all the questions asked from
the participants of the inspection.'' Id.
Respondent stated that she ``believed that it was not improper for
[her] to provide services [for Mercy] and that the practice was
operated appropriately'' and that she ``simply was not fully aware of
the obligations discussed in the paragraphs above and believed [she]
was in compliance with the laws.'' Id. Finally, Respondent stated that
``[t]his was the first time in [her] professional career that [she] had
been a dispensing practitioner and [that she is] not interested in
dispensing again after the experience [she] had with'' Mercy. Id.
Discussion
Section 303(f) of the Controlled Substances Act (CSA) provides that
an application for a practitioner's registration may be denied upon a
determination ``that the issuance of such registration . . . would be
inconsistent with the public interest.'' 21 U.S.C. 823(f). In making
the public interest determination in the case of a practitioner,
Congress directed that the following factors be considered:
(1) The recommendation of the appropriate State licensing board
or professional disciplinary authority.
(2) The applicant's experience in dispensing . . . controlled
substances.
[[Page 39334]]
(3) The applicant's conviction record under Federal or State
laws relating to the manufacture, distribution, or dispensing of
controlled substances.
(4) Compliance with applicable State, Federal, or local laws
relating to controlled substances.
(5) Such other conduct which may threaten the public health and
safety.
Id.
``[T]hese factors are considered in the disjunctive.'' Robert A.
Leslie, 68 FR 15227, 15230 (2003). I may rely on any one or a
combination of factors and may give each factor the weight I deem
appropriate in determining whether to deny an application. Id.
Moreover, I am ``not required to make findings as to all of the
factors.'' Hoxie v. DEA, 419 F.3d 477, 482 (6th Cir. 2005) (citing
Morall v. DEA, 412 F.3d 165, 173-74 (D.C. Cir. 2005)).
In the case of a practitioner, the Government has the burden of
proving with substantial evidence that granting an application would be
inconsistent with the public interest. However, where the Government
makes out a prima facie case to deny an application, the burden shifts
to the applicant to show why granting the application would be
consistent with the public interest.\3\
---------------------------------------------------------------------------
\3\ Where, as here, ``the Government has proved that a
registrant has committed acts inconsistent with the public interest,
a registrant must ```present sufficient mitigating evidence to
assure the Administrator that [he] can be entrusted with the
responsibility carried by such a registration.''''' Medicine Shoppe-
Jonesborough, 73 FR 364, 387 (2008) (quoting Samuel S. Jackson, 72
FR 23848, 23853 (2007) (quoting Leo R. Miller, 53 FR 21931, 21932
(1988))), aff'd, Medicine Shoppe-Jonesborough v. DEA, 300 Fed. Appx.
409 (6th Cir. 2008). ``Moreover, because `past performance is the
best predictor of future performance,' ALRA Labs, Inc. v. DEA, 54
F.3d 450, 452 (7th Cir. 1995), [DEA] has repeatedly held that where
a registrant has committed acts inconsistent with the public
interest, the registrant must accept responsibility for [his]
actions and demonstrate that [he] will not engage in future
misconduct.'' Medicine Shoppe, 73 FR at 387; accord Jackson, 72 FR
at 23853; John H. Kennedy, 71 FR 35705, 35709 (2006); Prince George
Daniels, 60 FR 62884, 62887 (1995). See also Hoxie v. DEA, 419 F.3d
at 483 (``admitting fault'' is ``properly consider[ed]'' by DEA to
be an ``important factor[]'' in the public interest determination).
In addition, ``DEA properly considers the candor of the
physician and his forthrightness in assisting in the investigation
and admitting fault important factors in determining whether the
physician's registration'' is consistent with the public interest.''
Hoxie, 419 F.3d at 483.
---------------------------------------------------------------------------
In this matter, I conclude that the Government's evidence with
respect to factors four and five establishes a prima facie case to deny
Respondent's application.\4\ While I have considered Respondent's
statement of position, I conclude that she has not provided substantial
evidence to show why, at this time, she can be entrusted with a new
registration.
---------------------------------------------------------------------------
\4\ The only evidence in the record as to factor one (the
recommendation of the state licensing board) is the approximately
one year old DOH report which shows that Respondent still had a
state license at that time. However, DEA has repeatedly held that
while the possession of state licensure is a fundamental condition
for obtaining and maintaining a practitioner's registration, it is
not dispositive of the public interest inquiry.
As for factor three, the Government raises no contention that
Respondent has been convicted of a federal or state law offense
related to controlled substances. However, because there are
multiple reasons why an applicant or registrant may not have been
convicted or even prosecuted for such an offense, the absence of
such a conviction ``is of considerably less consequence in the
public interest inquiry.'' Dewey C. MacKay, 75 FR 49956, 49973
(2010), pet. for rev. denied 2011 WL 6739420 (10th Cir., Dec. 23,
2011). See also Jayam Krishna-Iyer, 74 FR at 459, 461 (2009); Edmund
Chein, 72 FR 6580, 6593 n.22 (2007), pet. for rev. denied 533 F.3d
828 (DC Cir. 2008). Accordingly, this factor is not dispositive.
---------------------------------------------------------------------------
Factors Four and Five--Compliance With Applicable Laws Related to
Controlled Substances and Other Conduct Which May Threaten Public
Health and Safety
Based on the DOH Inspection, the Government alleges that Respondent
committed multiple violations of the CSA, its implementing regulations,
as well as Florida law and regulations. These violations include her
failure to conduct an initial inventory of the controlled substances,
her failure to institute sufficient security/diversion controls, and
her improper execution of a DEA 222 form for the transfer of controlled
substances from the clinic's prior doctor.
The CSA provides in relevant part that ``every registrant . . .
shall . . . as soon . . . as such registrant first engages in the
manufacture, distribution, or dispensing of controlled substances . . .
make a complete and accurate record of all stocks thereof on hand.'' 21
U.S.C. 827(a)(1).\5\ Respondent acknowledged that she failed to comply
with this provision. This was also a violation of Florida law. See Fla.
Stat. Ann. Sec. 893.07(1)(a).
---------------------------------------------------------------------------
\5\ While the CSA exempts from the recordkeeping requirements
``the prescribing of controlled substances . . . by practitioners
acting in the lawful course of professional practice unless such
substance is prescribed in the course of maintenance or
detoxification treatment of an individual,'' 21 U.S.C. 827(c)(1)(A),
the evidence shows that Respondent was not only prescribing but also
dispensing controlled substances.
---------------------------------------------------------------------------
The Government further argues that Respondent ``could not specify
what quantity of drugs she received from Dr. [W.'s] stock of controlled
substances, thus violating 21 CFR 1304.22.'' Req. for Final Agency
Action, at 5. This, however, is simply the same violation as set forth
in the preceding paragraph.\6\
---------------------------------------------------------------------------
\6\ The Government also alleges that Respondent violated Federal
law when she ``signed a DEA Form 222 to take possession of
controlled substances that were abandoned by a former practitioner
at the clinic.'' Show Cause Order at 2. As noted above, in an
affidavit, a DOH Investigator stated that ``there was no
documentation to support that Dr. [W.] authorized such a transaction
either personally or through [a] power of attorney.'' GX 5, at 53.
Given the Government's assertion that the drugs ``were abandoned,''
it is not clear why it was necessary for Dr. W. to authorize the
transaction and why Respondent violated Federal law by signing a
Form 222. The Government makes no further argument that it was
unlawful for Respondent to acquire possession of the controlled
substances that were at the clinic when she commenced her employment
there because the clinic owners were not registered and could not
lawfully distribute the drugs to her.
---------------------------------------------------------------------------
The Government also contends that Respondent violated Federal
regulations because she allowed other persons to order controlled
substances on her behalf and did not issue a Power of Attorney. The
Government argues that although Respondent signed several Schedule II
order forms which were ``completed by another individual, she did not
order the medications and she was not notified when controlled
substances were ordered on her behalf.'' Id. at 5; see also Show Cause
Order ] 2d (citing 21 CFR 1305.05(a)). As found above, Respondent
admitted that she did not know the amount of the drugs that were being
ordered under her registration. Yet other evidence establishes that the
DEA 222 forms were completed by the pharmacy technician and then signed
by Respondent.
Under the CSA, a schedule II controlled substance can only be
distributed pursuant to ``a written order of the person to whom such
substance is distributed, made on a form . . . issued by the Attorney
General [DEA-222].'' 21 U.S.C. 828(a). DEA regulations further provide,
in relevant part, that ``[o]nly persons who are registered . . . under
section 303 of the [CSA] to handle Schedule I or II controlled
substances . . . may obtain and used DEA Form 222 . . . for these
substances. Persons not registered to handle Schedule I or II
controlled substances . . . are not entitled to obtain Form 222.'' 21
CFR 1305.04(a). A registrant may, however, ``authorize one or more
individuals . . . to issue orders for Schedule I and II controlled
substances on the registrant's behalf by executing a power of attorney
for each such individual.'' Id. 1305.05(a).
The evidence does not, however, establish that Respondent violated
either the CSA or the Agency's regulations by signing the order forms
because the evidence shows that the forms were completed by the
pharmacy technician and then signed by Respondent. Thus, because
Respondent signed the form, she and not the pharmacy technician issued
the orders,
[[Page 39335]]
and Respondent was not required to execute a power of attorney form.
However, Respondent admitted that she did not know what controlled
substances were being ordered under her registration as well as when
they were being received, and the evidence shows that other scheduled
drugs including hydrocodone, alprazolam, and diazepam (which do not
require the execution of a Form 222 to order) were found at the clinic.
Moreover, other evidence establishes that the clinic did dispense
controlled substances (notwithstanding that Respondent had been at the
clinic for only seventeen days at the time of the inspection) which
were ordered under her registration. Under DEA's regulations applicable
to all registrants, a practitioner is required to institute and
maintain an adequate system ``for monitoring the receipt . . .
distribution, and disposition of controlled substances.'' 21 CFR
1301.71(b)(14). Respondent did not comply with this requirement.
The CSA also requires that ``every registrant . . . manufacturing,
distributing, or dispensing a controlled substance or substances shall
maintain, on a current basis, a complete and accurate record of each
such substance manufactured, received, sold, delivered, or otherwise
disposed of by him.'' Id. Sec. 827(a)(3). Florida law imposes a
similar obligation on persons engaged in the dispensing of controlled
substances. See Fla. Stat. Ann. Sec. 893.07(b). However, the record
does not establish whether the clinic was maintaining the invoices
documenting the receipt of controlled substances or a proper dispensing
log.
The Government also alleges that ``Respondent failed to store [the]
controlled substances in a securely locked cabinet'' and that DOH
Investigators observed that multiple employees had access to the drug
dispensing room. Req. for Final Agency Action, at 4 (citing 21 CFR
1301.71(b)(11) and 1301.75(b)). As for the failure to store the
controlled substances in a securely locked cabinet, the DOH
Investigators stated that drugs were observed both in an open safe and
on a table in the pharmacy area. It is not clear why this would
constitute a violation if the clinic was then open and preparing
prescriptions for dispensing.
As for the observation that multiple employees had access to the
dispensing room, under DEA regulations, ``[a]ll applicants and
registrants shall provide effective controls and procedures to guard
against theft and diversion of controlled substances.'' 21 CFR
1301.71(a). Among the factors which DEA considers is ``[t]he adequacy
of supervision over employees having access to manufacturing and
storage areas.'' Id. at 1301.71(b)(11) (emphasis added). While the
affidavits state that multiple employees had access to the dispensing
room, the record is devoid of evidence establishing whether the
supervision of these employees was adequate.\7\
---------------------------------------------------------------------------
\7\ Agency regulations explicitly require that non-practitioner
registrants limit access to storage areas. See 21 CFR 1301.72(d)
(security requirements for non-practitioners; ``The controlled
substances storage areas shall be accessible only to an absolute
minimum number of specifically authorized employees.''). There is,
however, no similar requirement applicable to practitioners.
---------------------------------------------------------------------------
The evidence also shows that clinic personnel (including
Respondent) violated various provisions of State law. More
specifically, the evidence showed that the clinic employee who filled
the prescriptions and dispensed them was not licensed as a pharmacist,
but rather only as a pharmacy technician, and that Respondent, who was
registered as a dispensing physician, admitted that she did not verify
the prescriptions that were dispensed to the patients. Under Florida
law in effect at the time of the events at issue here, ``[a] person may
not dispense medicinal drugs unless licensed as a pharmacist or
otherwise authorized under this chapter to do so, except that a
practitioner authorized by law to prescribe drugs may dispense such
drugs to her or his patients in the regular course of her or his
practice in compliance with this section.'' Fla. Stat. Sec.
465.0276(1).\8\ See also Fla. Admin. Code r.64B16-27.1001(3) (``Only a
pharmacist may make the final check of the completed prescription
thereby assuming the complete responsibility for its preparation and
accuracy.'').
---------------------------------------------------------------------------
\8\ In addition, under Florida law, ``[a] person other than a
licensed pharmacist or pharmacy intern may not engage in the
practice of the profession of pharmacy, except that a licensed
pharmacist may delegate to pharmacy technicians who are registered
pursuant to this section duties, tasks, and functions that do not
fall within the purview of s. 465.003(13).'' Fla. Stat. Sec.
465.014(1). However, ``[a]ll such delegated acts shall be performed
under the direct supervision of a licensed pharmacist who shall be
responsible for all such acts performed by persons under his or her
supervision.'' Id. A dispensing practitioner ``must . . . [c]omply
with and be subject to all laws and rules applicable to pharmacists
and pharmacies, including, but not limited to'' chapter 465, which
regulates the practice of pharmacy. Id. Sec. 465.0276(2)(b).
---------------------------------------------------------------------------
In her written statement, Respondent repeatedly asserted that she
believed that the pharmacy technician was actually a licensed
pharmacist. I do not find this credible because the affidavit of one of
the DOH Investigators establishes that ``on the wall immediately inside
the dispensing room,'' there was an 8\1/2\ by 11 printout stating that
the employee who did the dispensing was a Registered Pharmacy
Technician. See also Fla. Admin. Code r.64B16-27.100(4) (``The current
registration of each registered pharmacy technician shall be displayed,
when applicable, in a conspicuous place in or near the prescription
department, and in such a manner that can be easily read by patrons of
said establishment.''). In his affidavit, the Investigator further
stated that when Respondent said that she did not ``know until today
that [J.F.] was not a pharmacist,'' he confronted her with the
information regarding the printout, to which Respondent replied that
she had ``never been in that room.''
However, in her written statement, Respondent stated that she had
been in the dispensing room and seen the technician prepare the labels,
count the pills and place them in the bottles for dispensing.
Unexplained by Respondent is how she could then have been unaware that
J.F. was not a licensed pharmacist. I thus reject Respondent's
contention that she believed that J.F. was a pharmacist and could
lawfully dispense medications. Moreover, it is a violation of the
Florida Medical Practice Act to ``delegat[e] professional
responsibilities to a person when the licensee delegating such
responsibilities knows or has reason to know that such person is not
qualified by training, experience, or licensure to perform them.'' Fla.
Stat. Ann. Sec. 458.331(w).
The DOH Investigators further found that the clinic did not have
pedigree documents for any of the drugs that were on hand. As noted
above, Respondent admitted that drugs were ordered under her DEA
registration during her time there. Florida law provides in relevant
part that ``[a] drug or device is adulterated . . . [i]f it is a
prescription drug for which the required pedigree paper \9\ is
nonexistent.'' Id. Sec. 499.006(10). Moreover, under state
regulations, ``[a] copy of the pedigree paper must be maintained by
each recipient,'' Fla. Admin Code r. 64F-12.012(3)(d), and for a
``permittee[] located in the state . . . must be readily available and
immediately retrievable, i.e., subject to inspection at the
[[Page 39336]]
permitted establishment during the inspection.'' Id. r.64F-
12.012(6)(b).
---------------------------------------------------------------------------
\9\ The pedigree paper ``must include either the proprietary
name or generic name with the name of the manufacturer, repackager,
or distributor as reflected on the label of the product; dosage
form; strength; container size; quantity by lot number; the name and
address of each owner of the prescription drug that is required to
be identified on the pedigree paper; the name and address of each
location from which it was shipped if different from the owner's;
and the transaction dates.'' Fla. Admin Code r. 64F-12.012(3)(a)1.
In addition, ``[t]he pedigree paper must clearly identify the
invoice to which it relate[s].'' Id.
---------------------------------------------------------------------------
As the forgoing demonstrates, Respondent failed to comply with a
variety of federal and state controlled substance laws and regulations
as well as state pharmacy laws and rules. As for the latter, while
these laws and rules are applicable to all prescription drugs and not
just controlled substances, these violations are properly considered
under factor five as other conduct which may threaten public health and
safety for two reasons. First, the violations involved the dispensing
of controlled substances. Second, violations of state pharmacy rules
and food and drug safety provisions are relevant (even if the conduct
did not involve controlled substances) in assessing the likelihood of
an applicant's future compliance with the CSA. See Paul Weir
Battershell, 76 FR 44359, 44368 (2011); Wonderyears, Inc., 74 FR 457,
458 n.2 (2009).
On the other hand, the record in this matter establishes that
Respondent's record of non-compliance with the CSA was limited to a
seventeen-day period. While it may be that this conduct would have
continued but for the DOH inspection, Respondent stated in her letter
that following the inspection she terminated her relationship at the
clinic and there is no evidence disputing this.\10\
---------------------------------------------------------------------------
\10\ Hanging over this matter is the dark cloud of evidence that
Mercy was a pain clinic and that Respondent was seeing some 60 to 65
patients a day to whom she was prescribing such drugs as oxycodone
30mg and 15mg, muscle relaxants such as carisoprodol, and Xanax
(alprazolam). However, evidence which creates only a suspicion of
wrongdoing does not constitute substantial evidence. See NLRB v.
Columbian Enameling & Stamping Co., Inc., 306 U.S. 292, 299-300
(1939). I therefore do not rely on it.
---------------------------------------------------------------------------
It is also acknowledged that Respondent's letter demonstrated some
degree of contrition. However, I do not find credible Respondent's
numerous assertions that she believed that JF was a licensed
pharmacist. In addition, while Respondent emphasizes that her
employment at Mercy ``was the first time in [her] professional career
that [she] had been a dispensing practitioner,'' and that she ``was
completely unaware that [she] had run afoul of the laws governing
dispensing practitioners,'' GX 6, at 1, ignorance of the law is no
excuse. See Patrick W. Stodola, 74 FR 20727, 20735 (2009) (quoting
Hageseth v. Superior Ct., 59 Cal. Rptr.3d 385, 403 (Ct. App. 2007) (a
``licensed health care provider cannot `reasonably claim ignorance' of
state provisions regulating medical practice'')). Indeed, in her
statement, Respondent explained that at the time she took her position,
she ``was doing due diligence'' on two internal medicine groups. One
must wonder why she did not make a similar effort to familiarize
herself with the various requirements applicable to the dispensing of
controlled substances under both the CSA and state laws, as well as the
manner in which Mercy's business was operated.
DEA can, of course, consider deterrence interests in determining
whether to grant or deny an application. See Joseph Gaudio, 74 FR
10083, 10094 (2009) (citing Southwood Pharmaceuticals, Inc., 72 FR
36487, 36504 (2007)). As I have previously explained, ```even when a
proceeding serves a remedial purpose, an administrative agency can
properly consider the need to deter others from engaging in similar
acts.''' Gaudio, 74 FR at 10094 (quoting Southwood, 72 FR at 36504
(citing Butz v. Glover Livestock Commission Co., Inc., 411 U.S. 182,
187-88 (1973)). ``The `[c]onsideration of the deterrent effect of a
potential sanction is supported by the CSA's purpose of protecting the
public interest,''' which is manifested in both 21 U.S.C. 823(f) and
824(a)(4). Gaudio, 74 FR at 10094 (quoting 72 FR at 36504).
All registrants are charged with knowledge of the CSA, its
implementing regulations, as well as applicable state laws and rules.
Moreover, those registrants who contemplate employment in circumstances
in which their registrations are used to operate clinics owned by non-
registrants need to recognize that there are serious consequences for
failing to comply with the Act and that they remain strictly liable for
all activities which occur under the authority of their registrations.
See, e.g., Robert Raymond Reppy, 76 FR 61154, 61157-58 (2011); Paul
Weir Battershell, 76 FR 44359, 44368 (2011); Paul Volkman, 73 FR 30630,
30643-44 (2008), pet. for rev. denied 567 F.3d 215 (6th Cir. 2009). It
is no excuse that the practitioner is not the employer of those persons
who perform controlled substance activities and lacks the power to hire
or fire the employee.
Accordingly, having considered the record as a whole, I conclude
that Respondent has not sufficiently demonstrated why she should be
entrusted with a new registration. I therefore hold that granting
Respondent's application would, at this time, be ``inconsistent with
the public interest.'' 21 U.S.C. 823(f). However, given that the
violations proved on this record were limited in both their scope and
duration, a new application should be given favorable consideration if
submitted no earlier than one year from the date of this Order,
provided that Respondent meets the following conditions: (1) That she
does not engage in any further misconduct, and (2) that she takes a
certified Continuing Medical Education course on controlled substance
handling and dispensing.
Order
Pursuant to the authority vested in me by 21 U.S.C. 823(f) and 28
CFR 0.100(b), I order that the application of Sigrid Sanchez, M.D., for
a DEA Certificate of Registration as a practitioner, be, and it hereby
is, denied. This order is effective July 31, 2013
Dated: June 20, 2013.
Michele M. Leonhart,
Administrator.
[FR Doc. 2013-15706 Filed 6-28-13; 8:45 am]
BILLING CODE 4410-09-P